Progresses on active targeting liposome drug delivery systems for tumor therapy.
10.7507/1001-5515.202110067
- Author:
Manyu ZHANG
1
;
Chenxi LOU
1
;
Aoneng CAO
1
Author Information
1. Institute of Nanochemistry and Nanobiology, Shanghai University, Shanghai 200444, P. R. China.
- Publication Type:Review
- Keywords:
Active targeting;
Liposome;
Tumor therapy
- MeSH:
Drug Carriers/therapeutic use*;
Drug Delivery Systems;
Humans;
Liposomes/therapeutic use*;
Neoplasms/drug therapy*
- From:
Journal of Biomedical Engineering
2022;39(3):633-638
- CountryChina
- Language:Chinese
-
Abstract:
Liposome is an ideal drug carrier with many advantages such as excellent biocompatibility, non-immunogenicity, and easy functionalization, and has been used for the clinical treatment of many diseases including tumors. For the treatment of tumors, liposome has some passive targeting capability, but the passive targeting effect alone is very limited in improving the drug enrichment in tumor tissues, and active targeting is an effective strategy to improve the drug enrichment. Therefore, active targeting liposome drug-carriers have been extensively studied for decades. In this paper, we review the research progresses on active targeting liposome drug-carriers based on the specific binding of the carriers to the surface of tumor cells, and summarize the opportunities, challenges and future prospects in this field.
